DermTech(DMTK) - 2023 Q4 - Annual Results

Exhibit 99.1 DERMTECH REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS -Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 55 percent year-over-year -Test revenue increased 38 percent versus the fourth quarter of 2022 -Estimated cash runway into the first quarter of 2025 SAN DIEGO – February 29, 2024 – DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-quarter 2023 finan ...